Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment
Garofalo, M., Saari, H., Somersalo, P., Crescenti, D., Kuryk, L., Aksela, L., Capasso, C., Madetoja, M., Koskinen, K., Oksanen, T., Mäkitie, A., Jalasvuori, M., Cerullo, V., Ciana, P., & Yliperttula, M. (2018). Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. Journal of Controlled Release, 283, 223-234. https://doi.org/10.1016/j.jconrel.2018.05.015
Julkaistu sarjassa
Journal of Controlled ReleaseTekijät
Päivämäärä
2018Tekijänoikeudet
© 2018 The Authors. Published by Elsevier B.V.
Standard of care for cancer is commonly a combination of surgery with radiotherapy or chemoradiotherapy. However, in some advanced cancer patients this approach might still remaininefficient and may cause many side effects, including severe complications and even death. Oncolytic viruses exhibit different anti-cancer mechanisms compared with conventional therapies, allowing the possibility for improved effect in cancer therapy. Chemotherapeutics combined with oncolytic viruses exhibit stronger cytotoxic responses and oncolysis. Here, we have investigated the systemic delivery of the oncolytic adenovirus and paclitaxel encapsulated in extracellular vesicles (EV) formulation that, in vitro, significantly increased the transduction ratio and the infectious titer when compared with the virus and paclitaxel alone. We demonstrated that the obtained EV formulation reduced the in vivo tumor growth in animal xenograft model of human lung cancer. Indeed, we found that combined treatment of oncolytic adenovirus and paclitaxel encapsulated in EV has enhanced anticancer effects both in vitro and in vivo in lung cancer models. Transcriptomic comparison carried out on the explanted xenografts from the different treatment groups revealed that only 5.3% of the differentially expressed genes were overlapping indicating that a de novo genetic program is triggered by the presence of the encapsulated paclitaxel: this novel genetic program might be responsible of the observed enhanced antitumor effect. Our work provides a promising approach combining anticancer drugs and viral therapies by intravenous EV delivery as a strategy for the lung cancer treatment.
...
Julkaisija
Elsevier BVISSN Hae Julkaisufoorumista
0168-3659Asiasanat
Julkaisu tutkimustietojärjestelmässä
https://converis.jyu.fi/converis/portal/detail/Publication/28085017
Metadata
Näytä kaikki kuvailutiedotKokoelmat
Lisenssi
Samankaltainen aineisto
Näytetään aineistoja, joilla on samankaltainen nimeke tai asiasanat.
-
Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery
Saari, Heikki; Turunen, Tiia; Lõhmus, Andres; Turunen, Mikko; Jalasvuori, Matti; Butcher, Sarah J.; Ylä-Herttuala, Seppo; Viitala, Tapani; Cerullo, Vincenzo; Siljander, Pia R. M.; Yliperttula, Marjo (Taylor & Francis, 2020)Extracellular vesicles (EVs) have been showcased as auspicious candidates for delivering therapeutic cargo, including oncolytic viruses for cancer treatment. Delivery of oncolytic viruses in EVs could provide considerable ... -
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
Saarenheimo, Jatta; Eigeliene, Natalja; Andersen, Heidi; Tiirola, Marja; Jekunen, Antti (Frontiers Media SA, 2019)Targeted therapies have allowed for an individualized treatment approach in non-small-cell lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy depend on genetic identification of personal ... -
Extracellular vesicles and high‐density lipoproteins : Exercise and oestrogen‐responsive small RNA carriers
Karvinen, Sira; Korhonen, Tia‐Marje; Sievänen, Tero; Karppinen, Jari E.; Juppi, Hanna‐Kaarina; Jakoaho, Veera; Kujala, Urho M.; Laukkanen, Jari A.; Lehti, Maarit; Laakkonen, Eija K. (Wiley, 2023)Decreased systemic oestrogen levels (i.e., menopause) affect metabolic health. However, the detailed mechanisms underlying this process remain unclear. Both oestrogens and exercise have been shown to improve metabolic ... -
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments
Hulmi, Juha J.; Nissinen, Tuuli A.; Penna, Fabio; Bonetto, Andrea (MDPI, 2021)Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and increased morbidity and mortality. Anticancer treatments have also been shown to contribute to sustainment or exacerbation ... -
Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy
Via, Jack Dalla; Daly, Robin M.; Owen, Patrick J.; Mundell, Niamh L.; Rantalainen, Timo; Fraser, Steve F. (Elsevier Inc., 2019)Androgen deprivation therapy (ADT) improves survival in men with advanced prostate cancer (PCa), but has been associated with compromised skeletal health and increased fracture risk. However, limited previous research has ...
Ellei toisin mainittu, julkisesti saatavilla olevia JYX-metatietoja (poislukien tiivistelmät) saa vapaasti uudelleenkäyttää CC0-lisenssillä.